Accretion mode changes in Centaurus X-3

We report here discovery of the existence of two different accretion modes in the high mass X-ray binary pulsar Cen X-3 during its high states. The multiband X-ray light curves of Cen X-3 lasting for more than 3400 days obtained with the All Sky Monitor (ASM) onboard the Rossi X-ray Timing Explorer (RXTE) shows many episodes of high and low X-ray intensities. The high intensity phases last between a few to upto 110 days and the separation between two high intensity phases also varies widely. One remarkable feature deduced from the RXTE-ASM light curves is that during these high intensity phases, Cen X-3 manifests in two very distinct spectral states. When the source makes a transition from the low intensity phase to the high intensity phase, it adopts one of these two spectral states and during the entire high intensity phase remains in that particular spectral state. During December 2000 to April 2004, all the high intensity episodes showed a hardness ratio which is significantly larger than the same during all the high states prior to and subsequent to this period. It is also found that most of the soft outbursts reach a nearly constant peak flux in the 5--12 keV band. For comparison, similar analysis was carried out on the long term X-ray light curves of three other X-ray binary pulsars Her X-1, Vela X-1, and SMC X-1. Results obtained with these sources are also presented here and we found that none of the other sources show such a behaviour. From these observations, we suggest that Cen X-3 has two different accretion modes and in the course of nine years it has exhibited two switch overs between these.Comment: 5 pages, 5 postscript figures, accepted for publication in Astronomy and Astrophysics Letter

Multi-wavelength Observations of the Giant X-ray Flare Galaxy NGC 5905: signatures of tidal disruption

NGC 5905 is one of the few galaxies with no prior evidence for an AGN in which an X-ray flare, due to the tidal disruption of a star by the massive black hole in the center of the galaxy, was detected by the RASS in 1990-91. Here we present analysis of late-time follow-up observations of NGC 5905 using Chandra, Spitzer VLA 3 GHz and 8 GHz archival data and GMRT 1.28 GHz radio observations. The X-ray image shows no compact source that could be associated with an AGN. Instead, the emission is extended -- likely due to nuclear star formation and the total measured X-ray luminosity is comparable to the X-ray luminosity determined from the 2002 Chandra observations. Diffuse X-ray emission was detected close to the circum-nuclear star forming ring. The Spitzer 2006 mid-infrared spectrum also shows strong evidence of nuclear star formation but no clear AGN signatures. The semi-analytical models of Tommasin et. al. 2010 together with the measured [OIV]/[NeII] line ratio suggest that at most only 5.6% of the total IR Flux at 19 $\mu$m is being contributed by the AGN. The GMRT 1.28 GHz observations reveal a nuclear source. In the much higher resolution VLA 3 GHz map, the emission has a double lobed structure of size 2.7'' due to the circumnuclear star forming ring. The GMRT 1.28 GHz peak emission coincides with the center of the circumnuclear ring. We did not detect any emission in the VLA 8 GHz (1996) archival data. The 3 $\sigma$ upper limits for the radio afterglow of the TDE at 1.28 GHz, 3 GHz and 8 GHz are 0.17 mJy, 0.09 mJy and 0.09 mJy, respectively. Our studies thus show that (i) NGC 5905 has a declining X-ray flux consistent with a TDE, (ii) the IR flux is dominated by nuclear star formation, (iii) the nuclear radio emission observed from the galaxy is due to circumnuclear star formation, (iv) no compact radio emission associated with a radio afterglow from the TDE is detected.Comment: 12 pages, 8 figures, accepted to be published in Astrophysics and Space Scienc

Pyrite surface characterization and control for advanced fine coal desulfurization technologies

This is the 9th quarterly technical progress report for the project entitled Pyrite surface characterization and control for advanced fine coal desulfurization technologies'', DE-FG22-90PC90295. The work presented in this report was performed from September 1, 1992 to November 31, 1992. The objective of the project is to conduct extensive fundamental studies on the surface chemistry of pyrite oxidation and flotation and to understand how the alteration of the coal-pyrite surface affects the efficiency of pyrite rejection in coal flotation. During this reporting period, the surface oxidation of pyrite in various electrolytes was investigated. It has been demonstrated, for the first time, that borate, a pH buffer and electrolyte used by many previous investigators in studying sulfide mineral oxidation, actively participates in the surface oxidation of pyrite. In borate solutions, the surface oxidation of pyrite is tronly enhanced. The anodic oxidation potential of pyrite is lowered by more than 0.4 volts. The initial reaction of the borate enhanced pyrite oxidation can be described by:FeS[sub 2] + B(OH)[sub 4][sup =] ------> [S[sub 2]Fe-B(OH)[sub 4]][sub surf] + e. This reaction is irreversible and is controlled by the mass-transfer of borate species from the solution to the surface. It has been shown that the above reaction inhibits the adsorption of xanthate on pyrite. Comparative studies have been made with other sulfide minerals. The solution chemistry of the iron-borate systems have been studied to understand the electrochemical results

Homozygous staggerer (sg/sg) mice display improved insulin sensitivity and enhanced glucose uptake in skeletal muscle

Homozygous staggerer (sg/sg) mice, which have decreased and dysfunctional Ror alpha (also known as Rora) expression in all tissues, display a lean and dyslipidaemic phenotype. They are also resistant to (high fat) diet-induced obesity. We explored whether retinoic acid receptor-related orphan receptor (ROR) alpha action in skeletal muscle was involved in the regulation of glucose metabolism

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): A study protocol for a randomised controlled trial

BACKGROUND: Tuberculosis (TB) in children is frequently paucibacillary and non-severe forms of pulmonary TB are common. Evidence for tuberculosis treatment in children is largely extrapolated from adult studies. Trials in adults with smear-negative tuberculosis suggest that treatment can be effectively shortened from 6 to 4 months. New paediatric, fixed-dose combination anti-tuberculosis treatments have recently been introduced in many countries, making the implementation of World Health Organisation (WHO)-revised dosing recommendations feasible. The safety and efficacy of these higher drug doses has not been systematically assessed in large studies in children, and the pharmacokinetics across children representing the range of weights and ages should be confirmed. METHODS/DESIGN: SHINE is a multicentre, open-label, parallel-group, non-inferiority, randomised controlled, two-arm trial comparing a 4-month vs the standard 6-month regimen using revised WHO paediatric anti-tuberculosis drug doses. We aim to recruit 1200 African and Indian children aged below 16 years with non-severe TB, with or without HIV infection. The primary efficacy and safety endpoints are TB disease-free survival 72 weeks post randomisation and grade 3 or 4 adverse events. Nested pharmacokinetic studies will evaluate anti-tuberculosis drug concentrations, providing model-based predictions for optimal dosing, and measure antiretroviral exposures in order to describe the drug-drug interactions in a subset of HIV-infected children. Socioeconomic analyses will evaluate the cost-effectiveness of the intervention and social science studies will further explore the acceptability and palatability of these new paediatric drug formulations. DISCUSSION: Although recent trials of TB treatment-shortening in adults with sputum-positivity have not been successful, the question has never been addressed in children, who have mainly paucibacillary, non-severe smear-negative disease. SHINE should inform whether treatment-shortening of drug-susceptible TB in children, regardless of HIV status, is efficacious and safe. The trial will also fill existing gaps in knowledge on dosing and acceptability of new anti-tuberculosis formulations and commonly used HIV drugs in settings with a high burden of TB. A positive result from this trial could simplify and shorten treatment, improve adherence and be cost-saving for many children with TB. Recruitment to the SHINE trial begun in July 2016; results are expected in 2020

Potential therapeutic applications of microbial surface-activecompounds

Numerous investigations of microbial surface-active compounds or biosurfactants over the past two decades have led to the discovery of many interesting physicochemical and biological properties including antimicrobial, anti-biofilm and therapeutic among many other pharmaceutical and medical applications. Microbial control and inhibition strategies involving the use of antibiotics are becoming continually challenged due to the emergence of resistant strains mostly embedded within biofilm formations that are difficult to eradicate. Different aspects of antimicrobial and anti-biofilm control are becoming issues of increasing importance in clinical, hygiene, therapeutic and other applications. Biosurfactants research has resulted in increasing interest into their ability to inhibit microbial activity and disperse microbial biofilms in addition to being mostly nontoxic and stable at extremes conditions. Some biosurfactants are now in use in clinical, food and environmental fields, whilst others remain under investigation and development. The dispersal properties of biosurfactants have been shown to rival that of conventional inhibitory agents against bacterial, fungal and yeast biofilms as well as viral membrane structures. This presents them as potential candidates for future uses in new generations of antimicrobial agents or as adjuvants to other antibiotics and use as preservatives for microbial suppression and eradication strategies